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Abstract
Accelerated atherosclerosis represents a major problem in both systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) patients, and endothelial damage is a key feature of atherogenesis. We aimed to assess early endothelial
changes in SLE and RA female patients (127 SLE and 107 RA) without previous CV events. Biomarkers of endothelial cell
activation (intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1), thrombomodulin (TM),
and tissue factor (TF)) were measured and endothelial function was assessed using peripheral artery tonometry. Reactive
hyperemia index (RHI), an indicator of microvascular reactivity, and augmentation index (AIx), a measure of arterial stiffness,
were obtained. In addition, traditional CV risk factors, disease activity and medication were determined. Women with SLE
displayed higher sICAM-1 and TM and lower TF levels than women with RA (p = 0.001, p,0.001 and p,0.001, respectively).
These differences remained significant after controlling for CV risk factors and medication. Serum levels of vascular
biomarkers were increased in active disease and a moderate correlation was observed between sVCAM-1 levels and lupus
disease activity (rho = 0.246) and between TF levels and RA disease activity (rho = 0.301). Although RHI was similar across the
groups, AIx was higher in lupus as compared to RA (p = 0.04). Also in active SLE, a trend towards poorer vasodilation was
observed (p = 0.06). In conclusion, women with SLE and RA present with distinct patterns of endothelial cell activation
biomarkers not explained by differences in traditional CV risk factors. Early vascular alterations are more pronounced in SLE
which is in line with the higher CV risk of these patients.
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Introduction
Chronic systemic inflammation predisposes to accelerated
atherosclerosis, a risk that is well known in systemic lupus
erythematosus (SLE) and in rheumatoid arthritis (RA) patients
[1]. Subclinical vascular lesions develop long before atherosclerosis
becomes clinically evident, and they progress more rapidly in SLE
[2] and RA [3] than in the general population. Traditional
cardiovascular (CV) risk factors do not fully explain this enhanced
risk, and the disease itself is considered an independent CV risk
factor [1]. In addition, the potential contribution of genetic
variants to the development of atherosclerosis in RA patients has
been recently highlighted [4,5]. However, the reported magnitude
of the CV risk is several times higher in SLE than in RA [6–9],
and the reason for this divergence is still incompletely understood.
Endothelial damage is considered the first step in the
pathogenesis of atherosclerosis. It correlates with disease progres-
sion and predicts CV events in the general population [10]. The
importance of endothelial cells (ECs) for vascular health is
highlighted by its crucial role in maintaining blood fluidity and
in regulating vascular tonus and permeability. Under basal
conditions ECs express molecules such as thrombomodulin
(TM), which prevent platelet aggregation and the activation of
the clotting cascade. Further platelet inhibition is achieved as a
result of nitric oxide (NO) synthesis, a major vascular relaxant with
anti-inflammatory and anti-proliferative properties. During the
inflammatory process, ECs undergo changes characterized by
enhanced expression of adhesion molecules, increased transen-
dothelial permeability, and loss of antithrombotic properties [11].
Pro-inflammatory cytokines suppress TM expression and promote
its cleavage and release into circulation [12]. In addition, they
induce the expression of tissue factor (TF), a procoagulant
molecule absent from the surface of the intact ECs [13], shifting
the balance towards a prothrombotic state. Furthermore, damaged
endothelium loses its ability to produce vasodilators, thus adding to
the vascular injury. Endothelial dysfunction is potentially a
reversible disorder. Indeed, in patients with active RA, the
infusion of infliximab, a chimeric antibody against TNF, has been
found to improve biomarkers of endothelial activation [14] and
transiently ameliorate endothelial function[15].
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In vivo, vascular function can be examined non-invasively by
quantifying biomarkers of endothelial activation/damage, by
measuring the ability of endothelium to release NO in response
to various stimuli or by assessing arterial wall stiffness [16].
Previous data indicate impaired endothelial function both in SLE
[17] and in RA patients [18] when compared to non-inflammatory
controls. Nevertheless it is unclear whether the magnitude of early
vascular changes is similar in these two diseases.
Given the clinical and pathophysiological particularities of SLE
and RA, we hypothesize that endothelial function is differently
disturbed in these two patient groups, which could explain the
different CV risk. Thus, the major aim of our study was to
compare endothelial cell function between SLE and RA as
assessed by the measurement of soluble vascular biomarkers and
by endothelial function testing, taking into account the presence of
traditional CV risk factors and systemic inflammation.
Materials and Methods
Subjects
Consecutive SLE and RA women fulfilling the ACR classifica-
tion criteria and free of clinically manifest CV disease were
recruited from the rheumatology clinics of Hospital Garcia de
Orta, Almada, and Hospital de Santa Maria, Lisbon, between
April 2009 and October 2010. A control group of women without
systemic inflammatory diseases was also recruited from the local
community and evaluated in the same period. Participants were
excluded if they were pregnant, breastfeeding, had impaired renal
function (defined as serum creatinine .1.5 mg/dl), or had
documented ischemic heart disease (previous infarction, revascu-
larization surgery, angina, or heart failure), cerebrovascular
disease (stroke or transient ischemic attack) or symptomatic
peripheral artery disease. The study was approved by the Ethics
Committee of both hospitals and was conducted in accordance
with the principles stated in the Declaration of Helsinki. All
participants gave written informed consent.
Clinical assessment
Demographic data, disease characteristics, current medication,
and CV risk profile including blood pressure, serum lipids, fasting
glycemia, smoking habits, and body mass index (BMI) were
obtained. Patients were diagnosed with hypertension if the
measured blood pressure was repeatedly $140/90 mm/Hg or if
they used antihypertensive medication. The diagnosis of diabetes
was made if fasting glucose level was $126 mg/dl, or if patients
were under pharmacological treatment. Participants were classi-
fied as obese if BMI was $30 Kg/m2. Disease activity was
evaluated using the SLE Disease Activity Index 2000 (SLEDAI
2K), [19] and in RA patients 28 joints were examined for
tenderness and swelling, and the 4 variable disease activity score
(DAS28) was calculated using erythrocyte sedimentation rate [20].
Disease activity was stratified according to the cutoffs of each
instrument [20,21]: remission (SLEDAI 2K=0 for SLE or
DAS28,2.6 for RA patients), low disease activity ($1 SLEDAI
2K,4, in the case of SLE, or $2.6 DAS28#3.2, in the case of
RA), and active disease (SLEDAI 2K$4 or DAS28.3.2, for SLE
and RA patients, respectively).
Fasting blood samples were obtained before any other
procedures for measurement of glucose, uric acid, lipids (total
cholesterol, high density lipoprotein (HDL) cholesterol, low density
lipoprotein (LDL) cholesterol, and triglycerides), inflammatory
mediators (C-reactive protein (CRP) and fibrinogen) and soluble
vascular biomarkers (sICAM-1, sVCAM-1, TM, and TF).
Quantification of soluble vascular biomarkers and
cytokines
Measurements were performed using commercial enzyme-
linked immunosorbent assay (ELISA) based methods according
to the manufacturers’ instructions. The Human sICAM-1
FlowCytomix Simplex Kit and the Human sVCAM-1 FlowCyto-
mix Simplex Kit (Bender MedSystems GmbH, Vienna, Austria)
were used for quantification of adhesion molecules, both using the
FlowCytomix TM Technology. Serum levels of TM were measured
using the Human Thrombomodulin ELISA Kit (Cell Sciences H,
Canton, MA, USA) and serum levels of TF were quantified using
the AssayMax Human Tissue Factor ELISA kit (Assaypro, St
Charles, Mo, USA).
Endothelial function tests
Endothelial function was assessed by peripheral artery tonom-
etry (PAT). PAT is a noninvasive operator-independent method
that evaluates changes in pulse wave amplitude before and after
reactive hyperemia. The inter-day variability of this technique in
our department is 11% (data not published). The exam was
performed using the EndoPAT 2000 device (Itamar Medical Ltd,
Cesarea, Israel) as described elsewhere [22] and by assessors
blinded to the clinical diagnosis. Briefly, patients were placed in a
quiet room, in supine position, with a specially designed finger
probe on the index finger of each hand, and a pressure cuff placed
on one arm. Patients were recommended to refrain from smoking
and drinking coffee or tea during the previous 24 hours and not to
eat for at least 6 hours preceding the exam. PAT was continuously
measured during a 10-minute baseline period, for 5 minutes after
the pressure cuff was inflated to suprasystolic pressure and for 10
additional minutes following the release of upper arm occlusion.
Pressure changes reflecting pulse amplitude were transmitted to a
computer and reactive hyperemia index (RHI) was calculated as
the ratio of PAT signal amplitude after cuff deflation divided by
the amplitude of baseline signal, adjusted for fluctuations in the
magnitude of the signal in the contralateral finger [22].
Augmentation index (AIx) was calculated from the mean PAT
waveform of the baseline period dividing the amplitude of the
second systolic peak by the difference between the second and the
first peak.
Statistical analysis
Continuous variables are expressed as means with standard
deviations and categorical variables as the number of affected
individuals and proportion of the total. Bivariate comparisons of
SLE and RA patients were made using Student T-tests, Mann-
Whitney, Kruskal-Wallis or x2 tests, as appropriate.
The levels of vascular biomarkers, as well as RHI and AIx, were
compared between SLE and RA patients first as crude means
using the Mann Whitney test, followed by analysis of covariance
(ANCOVA) to adjust for significant and clinically relevant baseline
covariates. Likewise, in order to assess the effect of disease activity
on vascular biomarkers, RHI and AIx, comparisons between
remission and active disease were performed.
Correlation between disease activity and endothelial cell
function was studied separately in SLE and RA using Spearman
correlation coefficient and partial correlations to control for age,
disease duration, cardiovascular risk factors and medication.
Statistical analysis was performed assuming a 5% significance
level and using SPSS 17 for Windows.
Early Vascular Alterations in SLE and RA
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Results
In total 127 women with SLE and 107 with RA, were included
in the study. A control group of 124 women, mean age
46.9613.7 years, 98% Caucasian, and 52% postmenopausal was
also evaluated as reference. Demographic and clinical character-
istics of SLE and RA patients are shown in Table 1. SLE women
were younger and had shorter disease duration (8.466.5 years)
compared to women with RA (10.767.3 years, p = 0.01). All lupus
patients were ANA positive and 89% of RA patients were positive
either for IgM RF or for anti-citrullinated protein antibodies. The
use of antimalarials and aspirin was more common in lupus, while
more RA patients received methotrexate. Serum concentration of
fibrinogen was higher in SLE (SLE 3266147 mg/dl vs RA
2766101 mg/dl; p = 0.01), but CRP levels were similar in both
groups (SLE 1.1663.2 mg/dl vs 1.0662.5 mg/dl; p = 0.75).
Vascular biomarkers and endothelial function as assessed
by PAT
A distinct pattern of soluble ECs biomarkers was identified in
SLE and in RA. While sICAM-1 and TM levels were significantly
higher, TF was lower in lupus than in RA patients (Figure 1).
Differences in sICAM-1, TM and TF remained significant after
adjustment for covariates (Table 2).
Reactive hyperemia was similar in SLE (RHI= 2.13560.686),
in RA (RHI=2.19460.810) and in the control population
(2.09060.579), while AIx was significantly higher in SLE as
compared to RA (16% vs 11%; p= 0.04), indicating increased
arterial wall stiffness in these patients. This increase remained
statistically significant after controlling for differences in baseline
characteristics (Table 2).
Disease activity and endothelial function
Patients presented a broad range of disease activity. The mean
SLEDAI 2K was 3.4664.5 (range 0 to 21) and the mean DAS28
was 4.1961.4 (range 1.70 to 7.54). Disease was in remission in
41% of SLE and in 17% of RA cases. 39% of SLE patients
presented moderate/high active disease defined as a SLEDAI
2K$4, and 72% of RA had moderate/high active disease
according to the DAS28 definition. Except for prednisolone
dosage, which was significantly higher in active SLE and active
RA than in remission, demographic characteristics, CV risk profile
and medication was comparable in quiescent and active disease.
Overall, serum levels of vascular biomarkers were elevated
when disease was active, being statistically significant the
differences in sICAM-1, TM and TF levels between active and
quiescent SLE and in sICAM-1 and TF levels between active RA
and remission (Table 3).
sVCAM-1 showed a significant Spearman and partial correla-
tion with lupus disease activity measured by the SLEDAI (rho
0.246 and 0.361; p = 0.007 and p,0.001 respectively) and TM
levels correlated with DAS28 (rho 0.301 and 0.250; p = 0.002 and
p= 0.005). In SLE patients there was also a significant correlation
between sVCAM-1, TM, TF and ESR (rho 0.246, 0.323 and
0.263; p= 0.01, p= 0.001 and p= 0.01, respectively) and between
serum TM levels and CRP (rho 0.315; p = 0.001). No significant
correlation was found in RA patients between ESR or CRP and
vascular biomarkers.
A trend toward lower RHI was observed in active SLE
(1.80660.16) as compared with remission (2.24960.13; p = 0.06),
but no significant correlation was observed between RHI, AIx and
SLEDAI or DAS28.
Discussion
In this comparative study we found distinct patterns of soluble
vascular biomarkers in SLE and in RA female patients free from
clinically evident CV disease. Lupus patients presented higher
serum sICAM-1 and TM levels, while TF was elevated in RA
patients. These findings are relevant for understanding the
pathophysiology of the increased CV risk in SLE and RA patients,
as cell adhesion molecules may represent a link between
inflammation and atherosclerosis. In fact, not only are VCAM-1
and ICAM-1 highly expressed on the endothelium overlaying
atherosclerotic lesions [23,24], but an increased serum concentra-
tion of these molecules is also related to CV risk factors [25] and
incident myocardial infarction [26]. In particular, high serum
levels of ICAM-1 represent an independent risk factor for
atherosclerosis and a predictor of future CV events [26,27]. In
addition, we observed significantly increased levels of vascular
biomarkers in active disease. These observations are in line with
previous studies demonstrating that inflammatory mediators,
including TNF, IL-6, interferon-gamma (INFc) [28], IL-18 [29],
but also MCP-1 and MIF [30], upregulate endothelial cell
adhesion molecule expression. The fact that SLE patients exhibit
higher sICAM-1 and also higher fibrinogen concentrations may be
relevant in the initiation and progression of atherosclerosis.
Indeed, ICAM-1 serves as a binding site for fibrinogen and
promotes adhesion and transendothelial migration of leukocytes
[31], an important early step in inflammatory vascular disease. We
did not find any difference in VCAM-1 serum levels among the
Table 1. Demographic and clinical characteristics of SLE and
RA women.
SLE (n =127) RA (n=107) p value
Demographic data
Age, years 43.9 (13.9) 50.2 (14.1) 0.01
Education, years 8.9 (4.8) 8.3 (5.2 ns
Caucasians, n (%) 110 (87) 95 (89) ns
Menopause, n (%) 60 (47) 62 (58) ns
Traditional CV risk factors
Current smoker, n (%) 18 (14) 17 (16) ns
Hypertension, n (%) 51 (40) 37 (35) ns
Total cholesterol, mg/dl 189.3 (42.8) 204.0 (33.5) 0.005
HDL cholesterol, mg/dl 56.6 (16.1) 63.9 (18.5) 0.002
LDL cholesterol, mg/dl 113.9 (36.6) 123.4 (28.5) 0.04
Triglycerides, mg/dl 125.7 (88.2) 103.1 (42.8) 0.01
Diabetes, n (%) 9 (7) 5 (5) ns
Obesity, n (%) 33 (26) 33 (31) ns
Medication
Antihypertensive, n (%) 51 (40) 32 (30) ns
Lipid lowering, n (%) 31 (24) 17 (16) ns
Aspirin, n (%) 28 (22) 6 (6) ,0.001
Hydroxychloroquine, n (%) 97 (74) 20 (19) ,0.001
Methotrexate, n (%) 12 (10) 85 (82) ,0.001
Prednisolone, mg/day 7.8 (10.9) 3.2 (3.5) 0.006
Results are presented as means (SD) or number of affected individuals and (%).
SLE – systemic lupus erythematosus; RA – rheumatoid arthritis; CV-
cardiovascular; HDL – high density lipoprotein; LDL – low density lipoprotein, ns
– non significant.
doi:10.1371/journal.pone.0044668.t001
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studied groups. In animal models, VCAM-1 expression is
considered a major early event in the atherosclerotic process
[32], and increased sVCAM-1 levels have been reported in lupus
nephritis [33]. However, in RA and SLE patients without renal or
vascular disease, serum concentrations of VCAM-1 are similar to
the control population and the relationship to atherosclerosis is
uncertain [34,35]. Nevertheless, very recently sVCAM-1 was
identified as an independent predictor of overall and cardiovas-
cular mortality in SLE[36].
Figure 1. Serum concentrations of vascular biomarkers in SLE and RA patients and non-inflammatory controls. sICAM-1– soluble
intercellular adhesion molecule; sVCAM-1 – soluble vascular cell adhesion molecule; RHI–reactive hyperemia index; Aix – augmentation index; SLE –
systemic lupus erythematosus; RA – rheumatoid arthritis.
doi:10.1371/journal.pone.0044668.g001
Table 2. Vascular biomarkers and results of PAT assessment in SLE and RA, after controlling for baseline covariates.
Age adjusted
Adjusted for CV risk factors, disease duration and
medication*
SLE (n=127) RA (n=107) p value SLE(n=127) RA(n =107) p value
sICAM ng/ml 1436 (600) 778 (651) 0.01 1994(879) 398(898) 0.05
sVCAM, ng/ml 1313 (114) 1129 (125) 0.29 1330 (159) 1160(162) 0.53
TM, ng/ml 6.59 (0.27) 4.54 (0.29) ,0.001 6.47 (0.36) 4.58(0.37) 0.003
TF, pg/ml 56.3 (10.1) 152.6 (10.9) ,0.001 50.1 14.4) 157(14.7) ,0.001
RHI1 2.128 (0.08) 2.203 (0.09) 0.53 2.008(0.11) 2.309(0.12) 0.12
AIx1, % 17.9 (1.9) 9.5 (2) 0.003 20.3 (2.5) 8.3 (2.7) 0.007
Results are presented as estimated marginal means (SE).
*Adjusted for the following covariates: age, disease duration, total cholesterol, HDL, LDL, triglycerides, aspirin, hydroxychloroquine, methotrexate use, and prednisolone
dose.
1RHI and AIx results refer to 87 women with SLE and 75 with RA.
sICAM-1 – soluble intercellular adhesion molecule; sVCAM-1 – soluble vascular cell adhesion molecule; TM – thrombomodulin; TF – tissue factor; RHI – reactive
hyperemia index; AIx – augmentation index.
doi:10.1371/journal.pone.0044668.t002
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There is growing evidence supporting the relationship between
inflammation and thrombotic complications of atherosclerosis
(atherothrombosis). Interestingly, TM expression, a molecule with
anti-coagulant properties, is reduced during the inflammatory
process [12], and increased soluble TM levels probably indicate
EC injury. Together with increased TF, which is an initiator of the
extrinsic coagulation cascade, this environment may raise the
thrombogenic activity of plasma and contribute to cardiovascular
events. Higher levels of TF in RA patients as compared to SLE
patients might be explained by the contribution of TNF to its
expression [37]. Nevertheless, serum levels of adhesion molecules,
TM, and TF may not accurately translate endothelial functional
expression of these molecules, which is a limitation of our work.
A further effect of proinflammatory cytokines on EC is the
inhibition of NO synthesis leading to endothelial dysfunction. In
the general population, impaired endothelial function is a critical
early step in the development of atherosclerosis [38] and predicts
the progression of structural arterial disease independently of
conventional CV risk factors [39,40]. However, studies of
endothelial function in inflammatory rheumatic diseases depicted
contradictory results [41–43], and the relevance of endothelial
dysfunction for the progression of atherosclerosis in rheumatic
diseases remains uncertain [44–46]. Similarly, the improvement
following anti-rheumatic medication is not universally supported
by the available literature [18]. Using PAT, we did not find any
significant differences in RHI neither between patients and
controls, nor between SLE and RA. RHI quantifies changes in
pulse wave amplitude in response to reactive hyperemia, a
measure of microvascular function. In the general population
RHI is an independent predictor of adverse cardiac events [47],
but its predictive value in rheumatic diseases has not been
established. The fact that we have included only females without
previous CV events and normal renal function (relatively low risk
population) may in part account for the comparable RHI found in
patients and controls. In fact, only in more active SLE cases did
RHI show a reduction. The follow up of these patients will allow
us to ascertain the predictive value of RHI measured by PAT for
the development of CV event in SLE and RA patients.
Lupus patients presented higher AIx than RA patients and this
difference remained significant after controlling for covariates. In
apparently healthy subjects arterial stiffness is an independent
predictor of coronary heart disease and stroke [48], but the
predictive value of AIx in rheumatic diseases is unknown.
Cardiovascular risk factors and disease related features contribute
to arterial stiffening in SLE [49] and RA [50]. Shang et al found a
correlation between carotid AIx and SLEDAI [51]. Increased
arterial stiffness was also associated with RA disease activity in
some, but not all, studies [18]. Increased AIx in SLE women
probably indicates a worse vascular condition.
Taken together, our observations add to the evidence that the
pathogenesis of atherosclerosis associated with inflammation may
differ in SLE and RA. Additionally, we found more pronounced
early vascular changes in lupus patients, and when the disease is
active, which is in line with the higher risk for CV events
documented in these patients.
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